Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Comprehensive update on the way

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Nov 13, 2020 8:41am

167 Views

Post# 31893904

RE:RE:Comprehensive update on the way

bringon10bagger wrote: and if I may add......this is super interesting......

Launched pipeline expansion initiatives aimed at developing new intellectual property based on the Company’s hydrogen sulfide platform.

MasterAlgae wrote: A total of eight Phase III-enabling studies now running in parallel.

Capital markets strategy to increase institutional awareness and liquidity.

Keep in mind there are 10 animal studies that are needed for Phase 3. Not sure how many of these 8 studies are related to Phase 3 enabling.